Purevax FeLV

RSS

vaccine against feline leukaemia

Authorised
This medicine is authorised for use in the European Union.

Overview

Purevax FeLV is a veterinary vaccine used to treat feline leukaemia in cats. It contains the active substance recombinant live canarypox virus (vCP97).

Purevax FeLV is used to vaccinate cats from the age of eight weeks against feline leukaemia, an illness affecting the immune system caused by a type of virus known as a retrovirus. The vaccine is used to prevent the symptoms of the disease and to prevent FeLV from remaining in the blood.

This EPAR was last updated on 17/02/2021

Authorisation details

Product details
Name
Purevax FeLV
Agency product number
EMEA/V/C/000056
Active substance
feline leukaemia virus recombinant canarypox virus (vCP97)
International non-proprietary name (INN) or common name
vaccine against feline leukaemia
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AD
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
13/04/2000
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Product information

14/08/2020 Purevax FeLV - EMEA/V/C/000056 - IB-0028

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Onset of immunity has been demonstrated 2 weeks after primary vaccination course.

The duration of immunity is one year after the last vaccination.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating